4[1]Jones P,Kafonek S,Laurora I,et al.Com parative dose efficacy study of atorvastatin versus simvastatin,pravastatin,lova statin,and fluvastatin in patients with hypercholesterolemia(The CURVES Study)[ J].Am J Cardiol,1998,81(5):582. 被引量：1
5[2]Keutz EV,Schluter G.Preclinical safety ev aluation of cerivastatin,a novel HMG-CoA reductase inhibitor[J].Am J Cardio l,1998,82(4):11J. 被引量：1
6[3]Chong PH,Seeger JD,Franklin C.Clinically relevant differences between the statins:implications for therapeutic selection [J].Am J Med,2001,111(5):390. 被引量：1
7[4]Rosenson RS,Tangney CC.Antiatherothrombot ic properties of statins[J].JAMA,1998,279(20):1643. 被引量：1
8[5]Meier CR,Schlienger RG,Kraenzlin ME,et al.HMG-CoA reductase inhibitors and the risk of fractures[J].JAMA,2000, 283(24):3205. 被引量：1
9[6]Weber W.Drug firm withdraws statin from t he market[J].Lancet,2001,358(9281):568. 被引量：1
10[7]Bernini F,Poli A,Paoletti R.Safety of HMG -CoA reductase inhibitor,focus on atorvastatin[J].Cardiovascular Drugs and Therapy,2001,15(3):211. 被引量：1
